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EBV-infected B cells are present in blood during acute infectious mononucleosis (IM) in sur-
prisingly large numbers. These cells share with cells transformed by EBV in vitro the capacity
for unlimited proliferation, but this capacity is quite restricted in the normal host. The unusual
extent of plasmacytic differentiation seen in infected cells in vivo early in IM and the loss of
this differentiation in the late stages of the disease suggest that these cells are subject to the
same immunoregulatory mechanisms that affect normal B cells. The host response to virus-
altered B cells is quite complex but is perhaps best viewed as an in vivo autologous mixed lym-
phocyte reaction initiated by the interaction of T cells with virus-activated B cells.
Infectious mononucleosis (IM) is a usually benign lymphoproliferative disease
that results from primary infection with Epstein-Barr virus (EBV). This virus, a
member ofthe herpes virus group, is unique among human pathogens in its tropism
for B lymphocytes and its capacity to induce the continuous proliferation ofinfected
cells in vitro [1]. In addition, the virus stimulates the synthesis and secretion of im-
munoglobulins by cells infected in vitro; for this reason it is frequently referred to as
a polyclonal activator of B cells [2]. In spite of the transforming capacity of EBV,
the major manifestation oflymphoproliferation in peripheral blood during IM is the
presence of large numbers of atypical lymphocytes, a majority of which have T lym-
phocyte characteristics [3]. Presumably, these cells are immunologically stimulated
in response to the disease. It should be emphasized that the lymphoproliferative pro-
cess in IM is not confined to blood, as lymphocytic infiltration can occur in lymph
nodes and in virtually any organ or tissue.
Much attention has been focused on various aspects of humoral and cellular im-
mune responses in IM, while studies on how EBV interacts with the cells it infects in
vivo have been relatively few, perhaps because of the difficulties involved in study-
ing these cells. However, it seems reasonable to presume that EBV-infected cells are
the initiators of the complex cascade of immunologic events that account for many
of the manifestations of the disease. Thus, knowledge of these cells-their number,
proliferative capacity, and stage of differentiation -is essential for a clear under-
standing of the pathogenesis of IM.
This review is not intended to be a comprehensive discussion of the pathogenesis
of IM but rather to summarize what has been learned about EBV-infected cells in
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the peripheral blood of mononucleosis patients. Much of what is discussed here is
based on results obtained from studies in our laboratory. Where it seems ap-
propriate, this information is interpreted in light of what is known about some
aspects of the immune response during IM.
PRESENCE AND NUMBER OF CIRCULATING EBV-INFECTED
LYMPHOCYTES IN IM
That EBV-infected lymphocytes were present in the blood of patients during IM
was originally inferred from the ready outgrowth of EBV-transformed cell lines
from cultured blood lymphocytes [4]. After primary EBV infection a lifelong carrier
state develops in which small numbers of latently infected cells are present in blood
and lymphoid tissues. Early estimates of the number of infected cells in the circula-
tion were based on a quantitative culture assay in microtiter plates in which the
minimum number of blood lymphocytes needed to give rise to cell lines was deter-
mined [5]. According to these estimates, as many as two in 10,000 circulating
mononuclear cells carried the virus during acute disease. This number decreased
during the course of the disease and during convalescence a minimum of 10' cells
was required to establish cell lines.
The demonstration that EBV nuclear antigen (EBNA) was expressed by infected
peripheral blood lymphocytes during IM [6,7] provided a more direct means to
study cells infected in vivo. In order to detect small numbers ofEBNA-positive cells,
T cells must first be removed from peripheral blood lymphocytes [6]. Thus, T cell-
depleted lymphocytes have been used in subsequent studies involving blood from
normal IM patients. The number of antigen-positive cells in the circulation depends
on the duration of clinical symptoms. By the end of the first week of illness, about
6-20 percent of this population of cells are EBNA-positive [8]. The number of
antigen-positive cells declines rapidly in the second week of illness and reaches low
levels (0.1-0.6 percent) during the third week. We have been unable to detect EBNA
after this time, although Katsuki et al. [7] have detected very small numbers of
EBNA-positive cells in IM blood taken as long as 4-8 weeks after onset.
These results show that there is an almost alarming number ofcirculating infected
cells late in the first week of IM. Since it is not possible to obtain blood specimens
earlier in the disease, it is not possible to know if even higher proportions ofantigen-
positive cells are present before a patient develops significant symptoms.
The decline in the number of EBNA-positive cells in blood during the course of
IM is most likely brought about through the action ofcytotoxic Tcells. Early studies
suggested that T cells with specific cytotxicity for EBV-transformed blood are
present in IM blood [9]. Further studies suggested that this cytotoxicity was not
restricted to HLA-compatible targets [10]. However, the specificity ofthese cells for
EBV-related targets is now being questioned. Recent evidence points to there being
several populations of T cells, which, when activated in vitro by mitogens or in
mixed lymphocyte cultures or in vivo during IM, are equally capable of killing EBV-
related and unrelated target cells [11]. Regardless oftheir specificity, these cytotoxic
cells probably play an important role in the elimination of EBV-infected cells.
Following IM or any primary EBV infection, long-term T-cell immunity with
specificity for EBV-transformed cells does develop [12]. The demonstration of cells
responsible for this immunity depends on an in vitro sensitization step involving ex-
posure of memory T cells to autologous EBV-transformed cells in order to generate
effector T cells. The cytotoxicity that develops appears to be specific for EBV-
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transformed cells and is HLA-restricted; i.e., requires HLA-compatible targets [12].
It is thought that such memory T cells are responsible for the control of latently in-
fected cells.
The antigen recognized by secondary cytotoxic T cells appears de novo on the cell
surface of B cells soon after infection. Whether it is a virus gene product or a unique
altered cellular antigen has not been determined. It has not as yet been serologically
defined.
PROLIFERATIVE CAPACITY OF EBV-INFECTED CELLS IN VIVO
The capacity of EBV to transform lymphocytes in vitro, together with the
presence of the virus in two human malignancies, Burkitt lymphoma and naso-
pharyngeal carcinoma, raises the question of whether the cells infected in vivo dur-
ing IM are actually transformed. Seeming to support this hypothesis was the
outgrowth of cell lines from cultured blood obtained during and after mono-
nucleosis. However, Rickinson et al. [13] found that cell lines from IM blood do not
necessarily represent progeny of cells infected in vivo. These investigators showed
that a majority of LCL growing from co-cultures of IM blood and human umbilical
cord blood did not arise from the patient's cells but were of fetal origin. Since the
cord blood lymphocyte population did not contain endogenous EBV, transfer of
virus from one population of cells to another had to occur to explain the results. In
addition, human serum containing EBV antibody markedly reduced the incidence of
spontaneous transformation.
Two conclusions from these observations were obvious: the transfer of infected
cells from the in vivo environment to in vitro conditions activates productive viral
replication in at least some of the genome-positive cells; an unknown proportion of
transformed cells that grow out from cultures of IM blood actually become infected
and transformed in vitro and do not represent progeny of circulating virus-carrying
cells. These results suggested to Rickinson et al. [13] that EBV genome-positive cells
in IM blood are only latently infected and that their growth properties were not af-
fected. However, the induction of lytic viral replication in explanted cells does not
exclude the possibility that EBV induces proliferation in the B cells that it infects in
vivo, since virus production can occur in established transformed cell lines [14].
There are now several lines ofevidence that support the concept that EBV causes a
primary B-cell proliferation in IM. The first is that colonies of EBNA-positive cells
can be grown from IM blood lymphocytes plated in semisolid medium [7]. Since the
conditions of this method of culture prevent the transfer of virus from cell to cell,
this finding suggests that at least some of the genome-positive cells are capable of
direct proliferation into transformed cell lines. One objection that can be raised here
is that clumps of cells could be plated together, allowing for the transfer of virus to
uninfected cells.
A second line of evidence supporting the hypothesis that EBV infection enhances
growth potential of B cells in vivo comes from studies in our laboratory in which we
demonstrated that some EBNA-positive cells could undergo mitosis while in the cir-
culation or shortly after being placed in culture [8]. Taking advantage of the
physical association of EBNA with metaphase chromosomes [15], we incubated B
lymphocytes, freshly isolated from IM patients in the first week of illness, with col-
cemid for two hours to arrest dividing cells in metaphase. Smears of these cells were
then stained for EBNA. In cells treated with colcemid immediately after the cells
were separated, only about one in 200 EBNA cells were in mitosis. Ifthe B cells were
313JAMES E. ROBINSON
cultured overnight (about 18 hours) at 37°C before exposing them to colcemid, a
burst of mitotic activity in the antigen-positive population occurred; 3-5 percent of
the cells with EBNA were in mitosis. These results are direct evidence that cir-
culating virus-carrying cells in acute IM have the potential to divide in vivo.
However, this proliferative potential appears to be restricted. Removal ofthe B cells
from the host resulted in increased mitotic activity, suggesting that the cells had been
released from the influence of an inhibitory environment.
The third line ofevidence that EBV infection ofB cells causes proliferation in vivo
comes from studies of patients who develop fatal lymphoproliferative syndromes
during primary EBV infection. A number of such patients have been reported-
some of them appear to have a genetic susceptibility which is X-linked, whereas
others occur sporadically in individuals of either sex and affect individuals of dif-
ferent ages [16]. The relationship of the lymphoproliferation in these patients to
EBV was firmly established when we studied a four-year-old girl who developed a
poorly differentiated lymphoplasmacytic malignancy during primary EBV infection
that presented initially as infectious mononulceosis [17]. The tumor cells and the
majority ofperipheral blood lymphocytes were EBNA-positive and contained multi-
ple copies of the EBV genome. The tumor was polyclonal in origin as direct cloning
of the cells in semisolid medium gave rise to cell lines that produced lambda and
kappa light chains. A number of patients with similar polyclonal B-cell tumors in
which EBNA or EBV-DNA is found have subsequently been reported. In every case,
including the one we studied, an underlying immune defect was either strongly
suspected or known to be present. The critical immune mechanisms that operate in
normal individuals to restrict the proliferation ofEBV-transformed cells in vivo, but
that are absent in patients in whom unchecked proliferation occurs, have not yet
been identified. Presumably cytotoxic and suppressor T cells, whether specific or
nonspecific, and humoral factors, such as antibodies, interferons, and lymphokines,
acting individually or in combination, are involved in these control mechanisms.
DIFFERENTIATION OF EBNA-POSITIVE CELLS IN IM
In the child who developed malignancy during IM, the tumor cells morpholog-
ically resembled plasma cells. Indeed, most of them contained not only EBNA but
also cytoplasmic immunoglobulins (clg) detectable by direct immunofluorescence
[17]. It was somewhat surprising to find that 45 percent ofthe peripheral blood lym-
phocytes synthesized cIgA, 15 percent cIgG, and only 2 percent cIgM. To determine
whether the degree of differentiation and the distribution of immunoglobulin heavy
chains in this patient was extraordinary, and, therefore, might suggest an unusual
host cell-virus interaction, we undertook a study of patients with uncomplicated IM.
Using two-color immunofluorescence which allowed the simultaneous identification
of EBNA-positive cells and the demonstration of cytoplasmic immunoglobulins, we
found that in the first week of illness 70-80 percent of the EBNA-positive cells also
contained cytoplasmic immunuglobulins and thus showed plasmacytic differentia-
tion. Heavy chain expression in these cells in six IM patients was similar to that seen
in the patient with fatal disease; i.e., EBNA-positive cells with cIgA and cIgG were
more common than were cells with cIgM [18].
As noted above, the number of EBNA-positive cells in IM blood decreased rap-
idly in the second and third weeks of illness. This decrease was accompanied by a loss
of differentiation, as clg was detected in a low proportion of the remaining EBNA-
positive cells. Cytoplasmic immunoglobulin synthesis may be inhibited in these in-
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fected cells by the suppressor T cells which have been shown to appear in the blood
of IM patients in the second week of illness [19,20]. These cells inhibit im-
munoglobulin secretion in B cells polyclonally activated in vitro by pokeweed
mitogen or by EBV and thus are not specific for EBV-infected cells [19,20]. It has
been proposed [20] that suppressor cells play a role in the depression of cell-
mediated immunity that characteristically occurs in IM [21].
EBV infection of B cells in itself is sufficient to cause some differentiation of B
cells [2], but preliminary observations in our laboratory show that cytoplasmic im-
munoglobulin synthesis occurs in fewer cells transformed in vitro than it does in vivo
during early IM. This suggests that circulating infected cells are subject to im-
munoregulation not only by suppressor but also by helper mechanisms. Helper fac-
tors that polyclonally activate B cells in vitro are known to be produced during
autologous mixed lymphocyte reactions [22]. Since EBV-transformed cells are very
potent stimulators of autologous T cells [23], it is reasonable to view the initial in-
teraction of host T cells with virus-altered B cells in terms of an in vivo mixed lym-
phocyte reaction which sets in motion the first wave of reactive lymphoprolifera-
tion. This initial activation of T cells could stimulate B-cell differentiation as well as
account for the presence ofnonspecifically cytotoxic T cells as has been proposed by
Klein et al. [11].
Patients with IM characteristically develop hypergammaglobulinemia and pro-
duce a number of unusual antibodies. These include Paul-Bunnell heterophil an-
tibodies, the presence of which is diagnostic of IM, and a number of autoreactive
antibodies. It has been widely assumed that B cells, polyclonally activated by EBV
infection in vivo, are the source ofthese antibodies [20]; however, our results do not
support this notion. The unusual antibodies in IM are almost always of the IgM
class. By contrast, most EBNA-positive cells produced IgG and IgA and relatively
few produced IgM. In addition, in some IM patients increased numbers of
uninfected plasmacytic cells were present [18], suggesting that normal B cells are
also activated in IM. This leaves open the possibility that uninfected, as well as in-
fected, B cells may be the source of the unusual antibodies that are produced in IM.
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